Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc ADR (NQ: SLN )

20.88 -0.21 (-1.00%)
Streaming Delayed Price Updated: 9:54 AM EDT, Jul 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Silence Therapeutics Plc ADR

< Previous 1 2 Next >
Silence Therapeutics to Buyback siRNA Complement Assets
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Present at SVB Securities Global Biopharma Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
From Silence Therapeutics
Via Business Wire
Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Silence Therapeutics
Via Business Wire
Silence Therapeutics Reports Third Quarter 2022 Results
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Present at Jefferies London Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in September Investment Conferences
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Pricing of Underwritten Offering
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Present at Jefferies Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports First Quarter 2022 Results
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at the American College of Cardiology (ACC) Annual Scientific Session and Expo
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics’ Head of Molecular Design Dr. Marie Wikström Lindholm Appointed to Oligonucleotide Therapeutics Society Board of Directors
From Silence Therapeutics plc
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.